KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Accumulated Expenses (2018 - 2023)

Vir Biotechnology's Other Accumulated Expenses history spans 6 years, with the latest figure at $9.7 million for Q1 2023.

  • On a quarterly basis, Other Accumulated Expenses fell 44.62% to $9.7 million in Q1 2023 year-over-year; TTM through Mar 2023 was $9.7 million, a 44.62% decrease, with the full-year FY2022 number at $12.7 million, up 23.96% from a year prior.
  • Other Accumulated Expenses hit $9.7 million in Q1 2023 for Vir Biotechnology, down from $12.7 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for VIR hit a ceiling of $21.4 million in Q3 2022 and a floor of $595000.0 in Q2 2020.
  • Historically, Other Accumulated Expenses has averaged $7.0 million across 5 years, with a median of $3.3 million in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 56.53% in 2019 and later soared 1173.79% in 2021.
  • Tracing VIR's Other Accumulated Expenses over 5 years: stood at $1.2 million in 2019, then crashed by 30.36% to $805000.0 in 2020, then soared by 1173.79% to $10.3 million in 2021, then increased by 23.96% to $12.7 million in 2022, then fell by 23.53% to $9.7 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for VIR at $9.7 million in Q1 2023, $12.7 million in Q4 2022, and $21.4 million in Q3 2022.